<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239421</url>
  </required_header>
  <id_info>
    <org_study_id>205.287</org_study_id>
    <nct_id>NCT00239421</nct_id>
  </id_info>
  <brief_title>A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Six-Week, Randomized, Double-Blind, Quadruple-Dummy Parallel Group Multiple Dose Study Comparing the Efficacy and Safety of Tiotropium Inhalation Capsules Plus Formoterol Inhalation Capsules to Salmeterol Inhalation Aerosol Plus Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol
      plus fluticasone in COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tiotropium (Spiriva®) is a once-daily inhaled anticholinergic for the treatment of COPD. A
      six-week, multicentre, randomized, double-blind, parallel group study was conducted to
      compare the efficacy and safety of the free combination of tiotropium 18 µg once daily plus
      formoterol 12 µg b.i.d. [Tio+For] to salmeterol 50 µg b.i.d. plus fluticasone 500 µg b.i.d.
      [Sal+Flu] in COPD patients. Information regarding the differential efficacy and safety of the
      two different combinations may be essential for physicians to make informed choices of
      therapy for COPD patients considered candidates for combination therapy.

      Following an initial screening visit, subjects entered a two or four-week run-in period in
      which they received ipratropium (Atrovent®) on a regular basis. At the second visit
      (Baseline), subjects were randomized into the six-week, double blind portion of the study in
      which they received either Tio+For or Sal+Flu. After three weeks of treatment, an interim
      visit was scheduled. After six weeks of treatment, a 12-hour profile of pulmonary function
      testings (FEV1, FVC) was obtained. Spirometric measurements were performed at pre-dose and 30
      minutes, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dosing. There were two co-primary endpoints:
      FEV1 area under the curve for the time period 0 to 12 hours (FEV1 AUC0-12) and peak FEV1.

      The efficacy evaluation (intention-to-treat) comprised 592 patients [Tio+For: N=297, Sal+Flu:
      N=295]. The two treatment groups were comparable with regard to demographic data and baseline
      disease characteristics [Baseline FEV1 (±SE): Tio+For: 1.310 L (±0.026 L); Sal+Flu: 1.325 L
      (±0.025 L)]. Adjustment was done for baseline and centre-effects.

      Study Hypothesis:

      The following primary hypotheses (one-sided) were tested with regard to superiority (all
      means are adjusted means):

      H01: FEV1AUC(0-12 hours) (tiotropium+formoterol) &lt;= FEV1AUC (0-12 hours)
      (salmeterol+fluticasone) versus H11: FEV1AUC(0-12 hours) (tiotropium+formoterol) &gt; FEV1AUC
      0-12 hours(salmeterol+fluticasone)

      It was stipulated in the protocol that, if the null hypothesis H01 was rejected in favour of
      H11, then the following hypothesis would be tested:

      H01: Peak FEV1 (tiotropium+formoterol) &lt;= Peak FEV1 (salmeterol+fluticasone) versus H11: Peak
      FEV1 (tiotropium+formoterol) &gt; Peak FEV1 (salmeterol+fluticasone)

      Each step was only considered confirmatory providing all previous steps were successful. If
      any of the previous steps were not successful, any analysis of the current step would have
      been considered descriptive.

      Comparison(s):

      Test therapy:

      Test product: Tiotropium inhalation capsules plus formoterol inhalation capsules Dose: 18 µg
      tiotropium per day (one capsule), 12 µg formoterol twice daily (two times one capsule) Mode
      of administration: inhalation via the Handihaler device (tiotropium), inhalation via the Blue
      Inhaler device (formoterol)

      Reference therapy:

      Test product: Salmeterol plus fluticasone propionate Dose: Salmeterol 50 µg (2 puffs of 25 µg
      each) b.i.d., fluticasone propionate 500 µg (2 puffs of 250 µg each) b.i.d.

      Mode of administration: inhalation via MDI

      The treatment duration was 42 days each. Primary endpoint measurements were performed on the
      last treatment day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date>September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable was forced expiratory volume in one second (FEV1). There were two co-primary endpoints: FEV1 area under the curve for the time period 0 to 12 hours [FEV1 AUC (0-12)] and peak FEV1 measured after 6 weeks of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints were trough FEV1, trough FVC, peak FVC and FVC AUC (0-12) measured at the same times as FEV1 after six weeks of treatment, individual FEV1 and FVC profiles, rescue medication use, peak expiratory flow, results of safety measurements.</measure>
  </secondary_outcome>
  <enrollment>605</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign an informed consent prior to participation in the trial, which
             includes medication washout and restrictions.

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease according
             to the GOLD criteria and must meet the following spirometric criteria:

             a post-bronchodilator FEV1 &lt; 80% of predicted normal, a post-bronchodilator FEV1/FVC &lt;
             70% at Visit 1, and a morning FEV1 &lt;= 65% predicted at Visit 2.

          3. Male or female patients 40 years of age or older.

          4. Patients must be current or ex-smokers with a smoking history of more than 10
             pack-years.

          5. Patients must be able to perform technically acceptable pulmonary function tests.

          6. Patients must be able to inhale medication in a competent manner from the HandiHaler®
             device, the Blue Inhaler device, and from a metered dose inhaler (MDI).

        Exclusion Criteria:

          1. Patients with significant diseases other than COPD.

          2. Patients with a recent history (i.e., six months or less) of myocardial infarction.

          3. Patients who have been hospitalized for heart failure (NYHA class III or IV) within
             the past year.

          4. Any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring
             intervention or a change in drug therapy within the past year.

          5. Patients with a history of cancer within the last five years.

          6. Patients with known narrow-angle glaucoma.

          7. Patients with a history of asthma, allergic rhinitis or atopy or who have a total
             blood eosinophil count &gt;= 600/mm3.

          8. Patients with a history of life threatening pulmonary obstruction, or a history of
             cystic fibrosis or clinically evident bronchiectasis.

          9. Patients with known active tuberculosis.

         10. Patients with significant alcohol or drug abuse within the past two years.

         11. Patients who have undergone thoracotomy with pulmonary resection.

         12. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to the Screening Visit (Visit 1) or patients who are currently in a pulmonary
             rehabilitation program that will not be maintained throughout the study.

         13. Patients who regularly use daytime oxygen therapy for more than one hour per day and
             in the investigator's opinion will be unable to abstain from the use of oxygen
             therapy.

         14. Patients who are being treated with antihistamines (H1 receptor antagonists) for
             asthma or excluded allergic conditions.

         15. Patients who have taken an investigational drug within one month or six half lives
             prior to Visit 1.

         16. Patients who have been treated with oral beta-adrenergics within one month prior to
             Visit 1.

         17. Patients who have been treated with antileukotrienes or leukotriene receptor
             antagonists for any disease within one month prior to Visit 1.

         18. Patients who have been treated with oral steroids within six weeks prior to Visit 1.

         19. Patients who have been treated with monoamine oxidase inhibitors or tricyclic
             antidepressants within one month prior to Visit 1.

         20. Patients who have been treated with cromolyn sodium or nedocromil sodium within one
             month prior to Visit 1.

         21. Patients who have been treated with inhaled steroids within two months prior to Visit
             1, including combinations of inhaled steroids and long-acting beta-adrenergics.

         22. Patients with known hypersensitivity to anticholinergic drugs, beta adrenergics,
             lactose or any other components of the inhalation capsule delivery system or any other
             components of the aerosol delivery systems.

         23. Pregnant or nursing women or women of childbearing potential not using a medically
             approved means of contraception for the previous three months.

         24. Patients with any respiratory infections in the six weeks prior to the Screening Visit
             (Visit 1) or during the run-in period.

         25. Patients who are currently participating in another study.

         26. Patients requiring more than eight puffs of salbutamol on three or more consecutive
             days during the run-in period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Med. Uni.-Klinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1120</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Vincentius Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Notre Dame des Bruyères</name>
      <address>
        <city>Chênée</city>
        <zip>4032</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilig Hartziekenhuis Campus Menen</name>
      <address>
        <city>Menen</city>
        <zip>8930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vosselaar</city>
        <zip>2350</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungemedicinsk Forskning 2B</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amtssygehuset i Gentofte</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Germon et Gauthier</name>
      <address>
        <city>Beuvry</city>
        <zip>62660</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lagord</city>
        <zip>17140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Louvière</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13597</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDARS GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinGuard GmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamed Research GmbH &amp; Co. KG</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <zip>63571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>am Krankenhaus Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH &amp; Co. KG</name>
      <address>
        <city>Leipzig</city>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universtität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <zip>80634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poli Longziekten</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>lokatie Langendijk</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polikliniek Longziekten</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poli Longziekten</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afdeling CardioSearch</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Centre</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCT Lung Institute</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Augustine Hospital</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QdotPharma</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung- och allergikliniken, Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <zip>S-551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endokrinologmott/Medicinkliniken</name>
      <address>
        <city>Motala</city>
        <zip>591 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung och allergikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung och allergikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung- och allergikliniken, Universitetssjukhuset</name>
      <address>
        <city>Umeå</city>
        <zip>S-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

